专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20160303169A9 SKELETAL MUSCLE AUGMENTATION UTILIZING MUSCLE-DERIVED PROGENITOR COMPOSITIONS, AND TREATMENTS THEREOF 有权
公开(公告)号：US20160303169A9
公开(公告)日：2016-10-20
申请号：US12245379
申请日：2008-10-03
申请人： Thomas Payne , Ronald Jankowski , Ryan Pruchnic , Michael Chancellor
发明人： Thomas Payne , Ronald Jankowski , Ryan Pruchnic , Michael Chancellor
IPC分类号： A61K35/34
CPC分类号： A61K35/34 , A61K9/0019 , A61K35/12 , C12N5/0658 , C12N5/0659 , C12N2500/84 , C12N2501/70 , C12N2510/00 , C12N2510/02 , C12N2533/54
摘要： The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. The invention also relates to novel uses of muscle-derived progenitor cells for the treatment of cosmetic or functional conditions, including, but not limited to skeletal muscle weakness, muscular dystrophy, muscle atrophy, spasticity, myoclonus and myalgia. The invention also relates to the novel use of MDCs for the increase of skeletal muscle mass in athletes or other organisms in need of greater than average skeletal muscle mass.

2. 发明申请

US20090098094A1 SKELETAL MUSCLE AUGMENTATION UTILIZING MUSCLE-DERIVED PROGENITOR COMPOSITIONS, AND TREATMENTS THEREOF 有权
标题翻译：使用肌肉衍生的孕激素组合物的骨骼肌肉康复治疗及其治疗
公开(公告)号：US20090098094A1
公开(公告)日：2009-04-16
申请号：US12245379
申请日：2008-10-03
申请人： Thomas Payne , Ronald Jankowski , Ryan Pruchnic , Michael Chancellor
发明人： Thomas Payne , Ronald Jankowski , Ryan Pruchnic , Michael Chancellor
IPC分类号： A61K35/34
CPC分类号： A61K35/34 , A61K9/0019 , A61K35/12 , C12N5/0658 , C12N5/0659 , C12N2500/84 , C12N2501/70 , C12N2510/00 , C12N2510/02 , C12N2533/54
摘要： The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. The invention also relates to novel uses of muscle-derived progenitor cells for the treatment of cosmetic or functional conditions, including, but not limited to skeletal muscle weakness, muscular dystrophy, muscle atrophy, spasticity, myoclonus and myalgia. The invention also relates to the novel use of MDCs for the increase of skeletal muscle mass in athletes or other organisms in need of greater than average skeletal muscle mass.
摘要翻译：本发明提供了肌肉衍生的祖细胞，其在移植到身体组织中后显示出长期存活，并且可以在引入（例如通过注射，移植或植入）之后增加软组织到软组织部位中。还提供了分离肌肉来源的祖细胞的方法，以及遗传修饰细胞用于基因转移治疗的方法。本发明进一步提供使用包含肌肉来源的祖细胞的组合物的方法，用于增加和膨胀哺乳动物，包括人类软组织，以治疗各种美容或功能状况，包括畸形，损伤，无力，疾病或功能障碍。本发明还涉及肌肉衍生的祖细胞用于治疗化妆品或功能状况的新用途，包括但不限于骨骼肌无力，肌营养不良，肌肉萎缩，痉挛状态，肌阵挛和肌痛。本发明还涉及MDC在需要大于平均骨骼肌质量的运动员或其他生物体中增加骨骼肌质量的新用途。

3. 发明授权

US09499791B2 Skeletal muscle augmentation utilizing muscle-derived progenitor compositions, and treatments thereof 有权
标题翻译：使用肌肉来源的祖细胞组合物的骨骼肌增强及其治疗
公开(公告)号：US09499791B2
公开(公告)日：2016-11-22
申请号：US12245379
申请日：2008-10-03
申请人： Thomas Payne , Ronald Jankowski , Ryan Pruchnic , Michael Chancellor
发明人： Thomas Payne , Ronald Jankowski , Ryan Pruchnic , Michael Chancellor
IPC分类号： A61K35/34 , C12N5/077 , A61K35/12
CPC分类号： A61K35/34 , A61K9/0019 , A61K35/12 , C12N5/0658 , C12N5/0659 , C12N2500/84 , C12N2501/70 , C12N2510/00 , C12N2510/02 , C12N2533/54
摘要： The present invention provides muscle-derived progenitor cells (MDCs) that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction into a site of soft tissue. Also provided are methods of isolating MDCs. The invention further provides methods of using compositions comprising MDCs for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. The invention also relates to uses of MDCs for the treatment of cosmetic or functional conditions, including, but not limited to skeletal muscle weakness, muscular dystrophy, muscle atrophy, spasticity, myoclonus and myalgia. The invention also relates to the use of MDCs for the increase of skeletal muscle.
摘要翻译：本发明提供了肌肉衍生的祖细胞（MDCs），其在移植到身体组织中后显示出长期存活，并且可以在引入软组织部位后增加软组织。还提供了隔离MDC的方法。本发明还提供了使用包含MDC的组合物的方法，用于在治疗各种美容或功能状况（包括畸形，损伤，无力，疾病或功能障碍）的哺乳动物包括人类软组织的增加和膨胀中。本发明还涉及MDC用于治疗化妆品或功能状况的用途，包括但不限于骨骼肌无力，肌营养不良，肌肉萎缩，痉挛状态，肌阵挛和肌痛。本发明还涉及MDCs用于增加骨骼肌的用途。

4. 发明申请

US20050265978A1 Muscle-derived cells (MDCs) for treating muscle- or bone-related injury or dysfunction 有权
标题翻译：肌肉来源的细胞（MDCs）用于治疗肌肉或骨骼相关的损伤或功能障碍
公开(公告)号：US20050265978A1
公开(公告)日：2005-12-01
申请号：US11040900
申请日：2005-01-21
申请人： Michael Chancellor , Johnny Huard
发明人： Michael Chancellor , Johnny Huard
IPC分类号： A01N43/04 , A01N63/00 , A61K45/00 , A61K48/00 , C12N5/077 , C12N15/09 , C12N15/63 , C12N5/08
CPC分类号： A61K35/34 , C12N5/0658 , C12N5/0659 , C12N2501/105 , C12N2501/113 , C12N2501/115 , C12N2501/13 , C12N2510/00 , C12N2510/04
摘要： The present invention provides muscle-derived cells, preferably myoblasts and muscle-derived stem cells, genetically engineered to contain and express one or more heterologous genes or functional segments of such genes, for delivery of the encoded gene products at or near sites of musculoskeletal, bone, ligament, meniscus, cartilage or genitourinary disease, injury, defect, or dysfunction. Ex vivo myoblast mediated gene delivery of human inducible nitric oxide synthase, and the resulting production of nitric oxide at and around the site of injury, are particularly provided by the invention as a treatment for lower genitourinary tract dysfunctions. Ex vivo gene transfer for the musculoskeletal system includes genes encoding acidic fibroblast growth factor, basic fibroblast growth factor, epidermal growth factor, insulin-like growth factor, platelet derived growth factor, transforming growth factor-β, transforming growth factor-α, nerve growth factor and interleukin-1 receptor antagonist protein (IRAP), bone morphogenetic protein (BMPs), cartilage derived morphogenetic protein (CDMPs), vascular endothelial growth factor (VEGF), and sonic hedgehog proteins.
摘要翻译：本发明提供肌肉衍生的细胞，优选成肌细胞和来自肌肉的干细胞，其被遗传工程化以含有和表达这种基因的一个或多个异源基因或功能区段，用于在肌肉骨骼的位点或附近递送编码的基因产物，骨，韧带，半月板，软骨或泌尿生殖系疾病，损伤，缺陷或功能障碍。本发明特别提供离体成肌细胞介导的人诱导型一氧化氮合酶的基因递送以及所产生的损伤部位周围及其周围的一氧化氮，作为降低泌尿生殖道功能障碍的治疗。肌肉骨骼系统的离体基因转移包括编码酸性成纤维细胞生长因子，碱性成纤维细胞生长因子，表皮生长因子，胰岛素样生长因子，血小板衍生生长因子，转化生长因子-β，转化生长因子-α，神经生长的基因因子和白细胞介素-1受体拮抗蛋白（IRAP），骨形态发生蛋白（BMPs），软骨来源的形态发生蛋白（CDMPs），血管内皮生长因子（VEGF）和声音刺猬蛋白。

5. 发明申请

US20070028930A1 Active agent and formulations to minimize or alleviate bladder urgency and irritation and/or to enhance sexual function 审中-公开
标题翻译：活性剂和制剂以最小化或缓解膀胱的紧迫性和刺激性和/或增强性功能
公开(公告)号：US20070028930A1
公开(公告)日：2007-02-08
申请号：US11475834
申请日：2006-06-27
申请人： Michael Chancellor , Pradeep Tyagi , Jonathan Kaufman
发明人： Michael Chancellor , Pradeep Tyagi , Jonathan Kaufman
IPC分类号： A61B19/00
CPC分类号： A61K36/38
摘要： To treat premature ejaculation, delay ejaculation, or improve male sexual control, control bladder urgency and/or minimize or alleviate irritated bladder or bladder urgency, an effective amount of St. John's Wort extract rich in hyperforin is administered to a male prior to sexual intercourse, or to a male or female patient otherwise in need thereof.
摘要翻译：为了治疗早泄，延迟射精或改善男性的性控制，控制膀胱的紧迫性和/或最小化或缓解膀胱或膀胱的急迫性紧迫性，在性交前向男性施用有效量的圣约翰草提取物，，或对另外需要的男性或女性患者。

6. 发明申请

US20070003610A1 Application of lipid vehicles and use for drug delivery 审中-公开
标题翻译：脂质载体的应用和用于药物输送
公开(公告)号：US20070003610A1
公开(公告)日：2007-01-04
申请号：US11438912
申请日：2006-05-22
申请人： Michael Chancellor , Matthew Fraser , Yao-Chi Chuang , William de Groat , Leaf Huang , Naoki Yoshimura
发明人： Michael Chancellor , Matthew Fraser , Yao-Chi Chuang , William de Groat , Leaf Huang , Naoki Yoshimura
IPC分类号： A61K39/08 , A61K9/127 , A61K31/16 , A61K48/00
CPC分类号： A61K9/127 , A61K9/0034
摘要： The present invention relates to compositions and methods for the administration of lipid-based vehicles to treat various disorders, including bladder inflammation, infection, dysfunction, and cancer. In various aspects, the compositions and methods of the invention are useful for prolonged delivery of drugs, e.g., antibiotics, pain treatments, and anticancer agents, to the bladder, genitourinary tract, gastrointestinal system, pulmonary system, and other organs or body systems. In particular, the present invention relates to liposome-based delivery of vanilloid compounds, such as resiniferatoxin, capsaicin, or tinyatoxin, and toxins, such as botulinum toxin, for the treatment of bladder conditions, including pain, inflammation, incontinence, and voiding dysfunction. Further related are methods of using these vehicles alone or in conjunction with antibodies, e.g., uroplakin antibodies, to improve duration of liposome attachment, and provide a long-term intravesical drug delivery platform. The present invention specifically relates to antibody-coated liposomes that are useful for targeting specific receptors for drug, peptide, polypeptide, or nucleic acid delivery. In one particular aspect, the present invention relates to liposomes coated with antibodies against nerve growth factor (NGF) receptor and containing NGF antisense nucleic acids, which are used as a treatment for neurogenic bladder dysfunction.
摘要翻译：本发明涉及用于施用基于脂质的载体以治疗各种疾病（包括膀胱炎症，感染，功能障碍和癌症）的组合物和方法。在各个方面，本发明的组合物和方法可用于向膀胱，泌尿生殖道，胃肠系统，肺系统和其它器官或身体系统延长递送药物，例如抗生素，疼痛治疗和抗癌剂。特别地，本发明涉及用于治疗膀胱病症（包括疼痛，炎症，失禁和排尿功能障碍）的香草素化合物（例如树脂毒素，辣椒素或微量毒素）和毒素（例如肉毒杆菌毒素）的基于脂质体的递送。进一步相关的是单独使用这些载体或与抗体（例如尿布隆蛋白抗体）联合以改善脂质体附着持续时间并提供长期膀胱内药物递送平台的方法。本发明具体涉及可用于靶向用于药物，肽，多肽或核酸递送的特异性受体的抗体包被的脂质体。在一个特定方面，本发明涉及用抗神经生长因子（NGF）受体和含有NGF反义核酸的抗体包被的脂质体，其用作神经源性膀胱功能障碍的治疗。

7. 发明申请

US20080009774A1 Methods of diminishing permanent tissue markings and related apparatus 审中-公开
标题翻译：减少永久性组织标记和相关设备的方法
公开(公告)号：US20080009774A1
公开(公告)日：2008-01-10
申请号：US11811507
申请日：2007-06-11
申请人： Christopher Capelli , Michael Chancellor
发明人： Christopher Capelli , Michael Chancellor
IPC分类号： A61N7/02
CPC分类号： A61N7/02 , A61B18/203 , A61B2017/00769 , A61B2017/22008 , A61B2018/00452 , A61B2018/0047
摘要： A method of diminishing permanent tissue markings on a person caused by particles in the dermis includes applying ultrasound radiation to the tissue to generate cavitation bubbles and altering the tissue marking particles by collapse of the cavitation bubbles and transferring energy to the particles. The ultrasound radiation in one embodiment may have a frequency of about 15 KHz to 2 MHz and may be pulsed. The process may be repeated at the same location or other locations while resisting undesired, excessive bleeding of the dermis. The permanent tissue markings may be tattoos. The method may be used in conjunction with other methods of removing the permanent tissue markings, which may include laser, chemical agents, and biological agents. Related apparatus is enclosed.
摘要翻译：减少由真皮中的颗粒引起的人的永久性组织标记的方法包括对组织施加超声波辐射以产生空化气泡并通过空化气泡的塌陷并将能量转移到颗粒来改变组织标记颗粒。一个实施例中的超声波辐射可以具有约15KHz至2MHz的频率并且可以是脉冲的。该过程可以在相同的位置或其他位置处重复，同时抵抗真皮的不希望的，过度的渗血。永久性组织标记可以是纹身。该方法可以与去除永久性组织标记的其它方法一起使用，其可以包括激光，化学试剂和生物制剂。封闭有关装置。

8. 发明申请

US20070065416A1 Soft tissue and bone augmentation and bulking utilizing muscle-derived progenitor cells, compositions and treatments thereof 有权
标题翻译：使用肌肉来源的祖细胞的软组织和骨增大和膨胀，其组合物和处理
公开(公告)号：US20070065416A1
公开(公告)日：2007-03-22
申请号：US11505734
申请日：2006-08-17
申请人： Michael Chancellor , Johnny Huard , Christopher Capelli , Zhuqing Qu
发明人： Michael Chancellor , Johnny Huard , Christopher Capelli , Zhuqing Qu
IPC分类号： A61K35/12 , C12N5/08
CPC分类号： C12N5/0659 , A61K35/12 , A61K35/34 , C12N5/0658 , C12N2500/84 , C12N2501/70 , C12N2510/00 , C12N2533/54
摘要： The present invention provides muscle-derived progenitor cells that show long-term survival following transplantation into body tissues and which can augment soft tissue following introduction (e.g. via injection, transplantation, or implantation) into a site of soft tissue. Also provided are methods of isolating muscle-derived progenitor cells, and methods of genetically modifying the cells for gene transfer therapy. The invention further provides methods of using compositions comprising muscle-derived progenitor cells for the augmentation and bulking of mammalian, including human, soft tissues in the treatment of various cosmetic or functional conditions, including malformation, injury, weakness, disease, or dysfunction. In particular, the present invention provides treatments and amelioration for dermatological conditions, gastroesophageal reflux, vesico-ureteral reflux, urinary incontinence, fecal incontinence, heart failure, and myocardial infarction.
摘要翻译：本发明提供了肌肉衍生的祖细胞，其在移植到身体组织中后显示出长期存活，并且可以在引入（例如通过注射，移植或植入）之后增加软组织到软组织部位中。还提供了分离肌肉来源的祖细胞的方法，以及遗传修饰细胞用于基因转移治疗的方法。本发明进一步提供使用包含肌肉来源的祖细胞的组合物的方法，用于增加和膨胀哺乳动物，包括人类软组织，以治疗各种美容或功能状况，包括畸形，损伤，无力，疾病或功能障碍。特别地，本发明提供了用于皮肤病学，胃食管反流，膀胱输尿管反流，尿失禁，大便失禁，心力衰竭和心肌梗死的治疗和改善。

9. 发明申请

US20050238625A1 Muscle-derived cells (MDCs) for promoting and enhancing nerve repair and regeneration 有权
标题翻译：用于促进和增强神经修复和再生的肌源性细胞（MDC）
公开(公告)号：US20050238625A1
公开(公告)日：2005-10-27
申请号：US10832542
申请日：2004-04-26
申请人： Michael Chancellor , Johnny Huard , Brandon Minnery
发明人： Michael Chancellor , Johnny Huard , Brandon Minnery
IPC分类号： A61K35/12 , A61K35/34 , A61P25/00 , C12N5/077 , A61K48/00 , C12N5/08
CPC分类号： C12N5/0658 , A61K35/12 , A61K35/34
摘要： The present invention describes methods involving the use of muscle derived cells (MDCs), preferably obtained from skeletal muscle, to support the innervation and repair of damaged tissues and organs, particularly associated with nerve damage or neuropathy. The invention relates to MDCs for use in methods for promoting or enhancing innervation of nerve cells, particularly in the peripheral nervous system, and their ability to contribute to the development of neuronal tissue when MDCs are introduced at or near a tissue or organ site in need of repair due to injury, damage, disease, or dysfunction. Such methods are useful for the treatment of central and peripheral nervous system disorders and to alleviate, abate, or eliminate the symptoms of neurologic or neurodegenerative diseases in animals, particularly mammals, including humans. The methods are also useful for treating both nerve and muscle tissue following injury, damage, or dysfunction to these tissue types.
摘要翻译：本发明描述了使用优选从骨骼肌获得的肌肉衍生细胞（MDC）来支持损伤的组织和器官的神经支配和修复，特别是与神经损伤或神经病有关的方法。本发明涉及用于促进或增强神经细胞神经细胞，特别是周围神经系统神经支配的方法中使用的MDC，以及当将MDCs引入到需要的组织或器官部位处或附近时有助于神经元组织发育的能力由于受伤，损伤，疾病或功能障碍引起的修复。这样的方法可用于治疗中枢和周围神经系统疾病并减轻，减轻或消除动物，特别是包括人在内的哺乳动物的神经退行性疾病或神经变性疾病的症状。这些方法对于在损伤，损伤或这些组织类型的功能障碍之后治疗神经和肌肉组织也是有用的。

10. 发明申请

US20070122466A1 Sphingomyelin liposomes for the treatment of hyperactive bladder disorders 有权
标题翻译：鞘磷脂脂质体用于治疗膀胱过动症
公开(公告)号：US20070122466A1
公开(公告)日：2007-05-31
申请号：US11546025
申请日：2006-10-11
申请人： Michael Chancellor , Pradeep Tyagi , Matthew Fraser , Yao-Chi Chuang , William de Groat , Leaf Huang , Naoki Yoshimura
发明人： Michael Chancellor , Pradeep Tyagi , Matthew Fraser , Yao-Chi Chuang , William de Groat , Leaf Huang , Naoki Yoshimura
IPC分类号： A61K9/127
CPC分类号： A61K9/127 , A61K9/0034 , A61K9/1272 , Y02A50/469
摘要： The present invention provides pharmaceutical compositions and methods for the instillation of lipid vehicles comprised of liposomes containing sphingomyelin or sphingomyelin metabolites to prevent, manage, ameliorate and/or treat disorders involving neuropathic pain and aberrant muscle contractions, such as what occurs in bladder hyperactivity disorders such as interstitial cystitis (IC) in animals or humans in need thereof. Also provided is a liposome-based delivery of drugs, e.g., antibiotics, pain treatments and anticancer agents, to the bladder, genitourinary tract, gastrointestinal system, pulmonary system and other organs or body systems. In particular, liposome-based delivery of vanilloid compounds, such as resiniferatoxin, capsaicin, or tinyatoxin and toxins, such as botulinum toxin is provided for the treatment of bladder conditions, including pain, inflammation, incontinence and voiding dysftunction.
摘要翻译：本发明提供用于滴注含有鞘磷脂或鞘磷脂代谢物的脂质体的脂质载体的药物组合物和方法，以预防，治疗，改善和/或治疗涉及神经性疼痛和异常肌肉收缩的疾病，例如膀胱多动障碍作为有需要的动物或人类的间质性膀胱炎（IC）。还提供了对膀胱，泌尿生殖道，胃肠系统，肺系统和其他器官或身体系统的基于脂质体的药物递送，例如抗生素，疼痛治疗和抗癌剂。特别地，为了治疗膀胱状况，包括疼痛，炎症，失禁和排尿功能障碍，提供了香草素化合物（例如树脂毒素，辣椒素或微量毒素）和毒素（例如肉毒杆菌毒素）的基于脂质体的递送。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式